{"id":"91dccbb7-c30c-521c-8db4-5d9e1a84910c","stable_key":"e0801c92-7fd3-5cb2-82b7-dd82f010f3ed:ivermectin-rosacea-lesions","predicate":"reduces_in_trial","statement":"Topical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"0d0a4c8a-1d65-529a-ae9b-91f5034b963f","mechanism_event_label":"Topical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5.","subject":{"id":"416b9886-c6a5-5526-a8bf-b571a8d418bf","slug":"ivermectin","display_name":"Ivermectin","entity_type_key":"drug"},"object":{"id":"dfa26fb9-7573-59b3-9bcf-30f6fa9c7cd4","slug":"papulopustular-rosacea-lesions","display_name":"Inflammatory lesions of papulopustular rosacea","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0d0a4c8a-1d65-529a-ae9b-91f5034b963f","stable_key":"e0801c92-7fd3-5cb2-82b7-dd82f010f3ed:ivermectin-rosacea-lesions-event","event_type":"observed_relationship","label":"Topical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5.","description":"Topical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"416b9886-c6a5-5526-a8bf-b571a8d418bf","slug":"ivermectin","display_name":"Ivermectin","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"dfa26fb9-7573-59b3-9bcf-30f6fa9c7cd4","slug":"papulopustular-rosacea-lesions","display_name":"Inflammatory lesions of papulopustular rosacea","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"12 weeks, with extension to 36 weeks for relapse","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Humans with moderate-to-severe papulopustular rosacea","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Topical ivermectin 1% cream","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Relapse after discontinuation was common in both arms, 62.7% with ivermectin and 68.4% with metronidazole by week 36, and ivermectin has only been tested in moderate-to-severe disease.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Humans with moderate-to-severe papulopustular rosacea","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Topical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. (2018). https://pubmed.ncbi.nlm.nih.gov/29943217/ DOI: 10.1007/s13555-018-0249-y","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Topical","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Inflammatory facial lesions, with acaricidal activity against Demodex mites","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"587b6c50-0c44-5ffc-b390-786faf2fc84d","evidence_kind":"source_excerpt","locator":"Lines 233-242","start_line":233,"end_line":242,"excerpt":"## ivermectin-rosacea-lesions\nTopical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5.\nModel/species: Humans with moderate-to-severe papulopustular rosacea\nTissue/system: Inflammatory facial lesions, with acaricidal activity against Demodex mites\nExposure: Topical ivermectin 1% cream\nRoute: Topical\nDuration: 12 weeks, with extension to 36 weeks for relapse\nLimits: Relapse after discontinuation was common in both arms, 62.7% with ivermectin and 68.4% with metronidazole by week 36, and ivermectin has only been tested in moderate-to-severe disease.\nPrimary reference: Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. (2018). https://pubmed.ncbi.nlm.nih.gov/29943217/ DOI: 10.1007/s13555-018-0249-y\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"20818ddd-7b37-5226-a24b-7de007e80eb2","stable_key":"import-e0801c92-7fd3-5cb2-82b7-dd82f010f3ed","title":"Ivermectin: mechanism of action across parasite, host barrier and mammalian targets (2026-09-22)","document_type":"imported_text","citation_label":"Original AI-assisted curation of sixteen primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Study-specific citations, concentrations, negative findings and limitations retained. Not publisher full text.","file_path":"","sha256":"c7e1e0201cbd222f0c52b7981f078936ed39b617d747821ed6daa584c2b964a7","revision_id":"56746c3e-cdec-5b8f-a191-425de1a0a7ce","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}